Serum Marker Panels for Predicting Liver Fibrosis - An Update

The Clinical Biochemist. Reviews
John Joseph

Abstract

Fibrosis prediction is an essential part of the assessment and management of patients with chronic liver disease. Traditionally the gold standard for assessment of fibrosis is liver biopsy, but it suffers from various limitations including risk of patient injury and sampling error. As a result, noninvasive tests of hepatic fibrosis have been used in patients with chronic liver disease due to conditions such as hepatitis B and C, and alcoholic and non-alcoholic fatty liver disease. With the advent of new direct-acting antivirals, hepatic fibrosis staging is an important component of treatment decisions in the care of patients with chronic hepatitis C virus infection. Current limitations of the noninvasive biomarker models include a significant indeterminate range, and a predictive ability that is limited to only a few stages of fibrosis. However newer technologies and novel proteins identified by proteomics and genomics offer the possibility for further refinement and individualisation of biomarker fibrosis models in the future.

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Related Papers

Journal of Gastroenterology and Hepatology
Leon A Adams
Gastroenterology Clinics of North America
Michelle Lai, Nezam H Afdhal
World Journal of Gastroenterology : WJG
Rudolf-E Stauber, Carolin Lackner
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
I CarmonaM Romero-Gómez
Journal of Digestive Diseases
Kun Zhou, Lun Gen Lu
© 2022 Meta ULC. All rights reserved